Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...